Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJCVQN)

Drug Name

1-(3-benzylquinoxalin-2-yl)hydrazine Drug Info

Synonyms

2-benzyl-3-hydrazinoquinoxaline; 223929-23-5; 2-benzyl-3-hydrazinylquinoxaline; CHEMBL379678; 1-(3-benzylquinoxalin-2-yl)hydrazine; AC1LAIMJ; benzylhydrazinoquinoxaline; SCHEMBL7628856; 3-benzyl-2-hydrazinoquinoxaline; KS-00001USU; CTK7F1811; 3-benzylquinoxaline-2-ylhydrazine; DTXSID80333186; MolPort-009-195-340; (3-benzylquinoxalin-2-yl)hydrazine; ZINC6580943; SBB100772; BDBM50179015; 7662AD; AKOS005070001; RTR-063098; RP14269; AJ-56391; TR-063098; 2R-0102

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 488815
CAS Number: CAS 223929-23-5
TTD Drug ID: DMJCVQN

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[2]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[3]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[4]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[5]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[6]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[7]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[8]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[9]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[10]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6.
2	Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
3	Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
4	Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
5	MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
6	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
7	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
8	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
9	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
10	Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
11	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.